TY - JOUR
T1 - Advancing HIV Drug Resistance Technologies and Strategies
T2 - Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings
AU - Steegen, Kim
AU - van Zyl, Gert U.
AU - Claassen, Mathilda
AU - Khan, Aabida
AU - Pillay, Melendhran
AU - Govender, Subitha
AU - Bester, Phillip A.
AU - van Straaten, Johanna M.
AU - Kana, Vibha
AU - Cutler, Ewaldé
AU - Kalimashe, Monalisa N.
AU - Lebelo, Ramokone L.
AU - Moloi, Mokopi B.H.
AU - Hans, Lucia
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/7
Y1 - 2023/7
N2 - Monitoring of HIV drug resistance (HIVDR) remains critical for ensuring countries attain and sustain the global goals for ending HIV as a public health threat by 2030. On an individual patient level, drug resistance results assist in ensuring unnecessary treatment switches are avoided and subsequent regimens are tailored on a case-by-case basis, should resistance be detected. Although there is a disparity in access to HIVDR testing in high-income countries compared to low- and middle-income countries (LMICS), more LMICs have now included HIVDR testing for individual patient management in some groups of patients. In this review, we describe different strategies for surveillance as well as where HIVDR testing can be implemented for individual patient management. In addition, we briefly review available technologies for HIVDR testing in LMICs, including Sanger sequencing, next-generation sequencing, and some point-of-care options. Finally, we describe how South Africa has implemented HIVDR testing in the public sector.
AB - Monitoring of HIV drug resistance (HIVDR) remains critical for ensuring countries attain and sustain the global goals for ending HIV as a public health threat by 2030. On an individual patient level, drug resistance results assist in ensuring unnecessary treatment switches are avoided and subsequent regimens are tailored on a case-by-case basis, should resistance be detected. Although there is a disparity in access to HIVDR testing in high-income countries compared to low- and middle-income countries (LMICS), more LMICs have now included HIVDR testing for individual patient management in some groups of patients. In this review, we describe different strategies for surveillance as well as where HIVDR testing can be implemented for individual patient management. In addition, we briefly review available technologies for HIVDR testing in LMICs, including Sanger sequencing, next-generation sequencing, and some point-of-care options. Finally, we describe how South Africa has implemented HIVDR testing in the public sector.
KW - HIV drug resistance testing
KW - acquired drug resistance
KW - next-generation sequencing
KW - pretreatment drug resistance
KW - surveillance
UR - http://www.scopus.com/inward/record.url?scp=85164965009&partnerID=8YFLogxK
U2 - 10.3390/diagnostics13132209
DO - 10.3390/diagnostics13132209
M3 - Review article
C2 - 37443603
AN - SCOPUS:85164965009
SN - 2075-4418
VL - 13
JO - Diagnostics
JF - Diagnostics
IS - 13
M1 - 2209
ER -